Investigators Assess PARP Inhibitor-Abiraterone Combo as Frontline mCRPC Therapy

Rachel Narozniak
Published: Thursday, Aug 15, 2019
Andrew J. Armstrong, MD

Andrew J. Armstrong, MD

Seeking to explore an apparent synergy between agents, investigators are evaluating the PARP inhibitor olaparib (Lynparza) in combination with the hormone blocker abiraterone (Zytiga) in men with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents. The multicenter phase III PROpel study (NCT03732820) will enroll approximately 720 patients globally and randomize them to receive olaparib with abiraterone or placebo plus abiraterone.


Figure. Olaparib Plus Abiraterone as Frontline mCRPC Therapy1

Figure. Olaparib Plus Abiraterone as Frontline mCRPC Therapy1 Full data are expected to be presented at an umpcoming medical meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication